Robert F. Kennedy Jr. forcing Peter Marks out of the Food and Drug Administration has blown a hole in the agency’s leadership ranks and threatens to unmoor the oversight of drugs and vaccines from bedrock scientific principles. 

For biotech investors, Marks’ ouster is a worst-case scenario realized — an FDA riven by dysfunction and uncertainty. And it comes at a time when the sector is already suffering through a years-long public markets slump. 

A crisis in confidence at the FDA is potentially calamitous. Investing in biopharma companies becomes exceedingly difficult if the regulatory agency in charge of evaluating and approving life-saving (and money-making) medicines stops following predictable, well-established standards.

STAT+ Exclusive Story

Already have an account? Log in

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/monthGet Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 monthsGet Started

Then $399/year

Annual

$399

Save 15%

$399/yearGet Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A QuoteRequest A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/yearGet Started

$300 Annually per user

View All Plans